GSK in Talks to Buy U.S. Rare Tumor Specialist IDRx for up to $1 Bln, FT Says, Citing Sources

Dow Jones

01-09

--Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 billion, the Financial Times reports, citing unnamed sources.

--An announcement on the deal could be made ahead of the JPMorgan healthcare conference in San Francisco next week, the FT says, adding that talks are continuing and could still fail.

--GSK declined to comment and IDRx didn't immediately respond to requests for comment from the FT.

Full story: https://tinyurl.com/46u4zzup

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

January 09, 2025 01:35 ET (06:35 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2502006363"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502006363\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2502006363?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-09 14:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502006363","market":"fut","top_or_hot":-1,"title":"GSK in Talks to Buy U.S. Rare Tumor Specialist IDRx for up to $1 Bln, FT Says, Citing Sources","media":"Dow Jones","content":"<html><body><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  --Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 billion, the Financial Times reports, citing unnamed sources. \n</p>\n<p>\n  --An announcement on the deal could be made ahead of the JPMorgan healthcare conference in San Francisco next week, the FT says, adding that talks are continuing and could still fail. \n</p>\n<p>\n  --GSK declined to comment and IDRx didn't immediately respond to requests for comment from the FT. \n</p>\n<pre>\n \n</pre>\n<p>\n  Full story: https://tinyurl.com/46u4zzup \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Ian Walker at ian.walker@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 09, 2025 01:35 ET (06:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones & Company, Inc.\n</p>\n</font></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>GSK in Talks to Buy U.S. Rare Tumor Specialist IDRx for up to $1 Bln, FT Says, Citing Sources</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK in Talks to Buy U.S. Rare Tumor Specialist IDRx for up to $1 Bln, FT Says, Citing Sources\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-09 14:35</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  --Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 billion, the Financial Times reports, citing unnamed sources. \n</p>\n<p>\n  --An announcement on the deal could be made ahead of the JPMorgan healthcare conference in San Francisco next week, the FT says, adding that talks are continuing and could still fail. \n</p>\n<p>\n  --GSK declined to comment and IDRx didn't immediately respond to requests for comment from the FT. \n</p>\n<pre>\n \n</pre>\n<p>\n  Full story: https://tinyurl.com/46u4zzup \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Ian Walker at ian.walker@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 09, 2025 01:35 ET (06:35 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones & Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK.UK","symbol_name":"葛兰素史克","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2502006363","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502006363","pubTimestamp":1736404500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"--Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 billion, the Financial Times reports, citing unnamed sources.--An announcement on the deal could be made ahead of the JPMorgan healthcare conference in San Francisco next week, the FT says, adding that talks are continuing and could still fail.--GSK declined to comment and IDRx didn't immediately respond to requests for comment from the FT.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GSK.UK":"葛兰素史克","BK4532":"文艺复兴科技持仓","GSK":"葛兰素史克","BK4007":"制药","FT":"富兰克林通用信托","LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"英国《金融时报》援引消息人士的话称，葛兰素史克正在洽谈以高达10亿美元收购美国罕见肿瘤专家IDRx","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FT":1,"GSK":1,"GSK.UK":0.6},"content_text":"--Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 billion, the Financial Times reports, citing unnamed sources. \n\n\n  --An announcement on the deal could be made ahead of the JPMorgan healthcare conference in San Francisco next week, the FT says, adding that talks are continuing and could still fail. \n\n\n  --GSK declined to comment and IDRx didn't immediately respond to requests for comment from the FT. \n\n\n \n\n\n  Full story: https://tinyurl.com/46u4zzup \n\n\n \n\n\n  Write to Ian Walker at ian.walker@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2025 01:35 ET (06:35 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1}}}